Document:

Non-Qualified Stock Option Agreement

 Exhibit 10.18 
 THIS OPTION AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS.
THIS OPTION, AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF, MAY NOT BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS,
OR THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. 
 SURGI-VISION, INC. 
 NON-QUALIFIED STOCK OPTION AGREEMENT 
 THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) is made effective as of the
22nd day of December, 2009, by and between SURGIVISION,
INC., a Delaware corporation (the “Company”), and KIMBLE L. JENKINS (the “Optionee”). 
 WHEREAS, the Company desires to afford the Optionee an opportunity to purchase shares of the Company’s common stock, par value $.01 per share (the “Shares”), subject to the terms and conditions hereinafter set forth;

 NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows: 
 1. Grant of Option. 
 (a) The Company grants as of the date of this
Agreement the right and option (the “Option”) to purchase 266,608 Shares, in whole or in part (the “Option Stock”), at an exercise price of $2.41 per Share (the “Option Price”), on the terms and
conditions set forth in this Agreement. The Optionee, holder or beneficiary of the Option shall not have any of the rights of a stockholder with respect to the Option Stock until such person has become a holder of such Shares by the due exercise of
the Option and payment of the Option Payment (as defined in Section 3 below) in accordance with this Agreement. 
 (b) The Option shall be a non-qualified stock option. In order to comply with all applicable federal or state tax laws or regulations, the Company may take such action as it deems appropriate to insure that, if necessary, all applicable
federal, state or other taxes are withheld or collected from the Optionee. This Agreement is not subject to, and the Option is not granted under, the Company’s 2007 Stock Incentive Plan, as amended. 
 2. Exercise of Option. The Optionee may exercise the Option with respect to the percentage and number of shares set forth below from
and after the dates specified below: 
  

					
	 Cumulative
 Percentage Vested
	  	 Date of Vesting
	  	 Cumulative
 Options Exercisable

	 33.33%
	  	December 22, 2010	  	88,869
	 66.66%
	  	December 22, 2011	  	177,739
	 100%
	  	December 22, 2012	  	266,608

 3. Manner of Exercise. The Option may be exercised in whole or in part at any time
within the period permitted hereunder for the exercise of the Option, with respect to whole Shares only, by delivering written notice of intent to exercise the Option to the Company at its principal office no earlier than thirty (30) days and
no later than ten (10) days prior to the date upon which the Optionee desires to exercise all or any portion of the Option, stating the number of Shares to be purchased, the person or persons in whose name the Shares are to be registered and
each such person’s address and social security number. Such notice shall not be effective unless accompanied by payment in full of the Option Price for the number of Shares with respect to which the Option is then being exercised (the
“Option Payment”) and cash equal to the required withholding taxes as set forth by Internal Revenue Service and applicable State tax guidelines for the employer’s minimum statutory withholding. The Option Payment shall be made
in cash or cash equivalents. In addition, the Company’s Board of Directors or an authorized committee thereof, in its sole discretion, may permit the Option Payment to be made in whole or in part in the form of an option to acquire Shares
(based on the fair market value of such option on the date the Option is exercised, as determined by the Board of Directors or such committee). The Optionee shall not be entitled to tender Shares pursuant to successive, substantially simultaneous
exercises of the Option or any other stock option of the Company. 
 4. Adjustments. In the event that any unusual or
non-recurring transactions, including an unusual or non-recurring dividend or other distribution (whether in the form of an extraordinary cash dividend, dividend of Shares, other securities or other property), recapitalization, stock split, reverse
stock split, reorganization, merger, consolidation, split-up, spin-off, combination or other similar corporate transaction or event affects the Shares, then the Company shall, depending on the particular circumstances, in an equitable and
proportionate manner (and, as applicable, in such equitable and proportionate manner as is consistent with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder) either: (a) adjust any or all of
(i) the number of Shares or other securities of the Company (or number and kind of other securities or property) subject to the Option, provided that the number of Shares subject to the Option shall always be a whole number; and (ii) the
Option Price with respect to the Option; (b) provide for an equivalent award in respect of securities of the surviving entity of any merger, consolidation or other transaction or event having a similar effect; or (c) make provision for a
cash payment to the Optionee in lieu of the Option. 
 5. Termination of Option. The Option will expire as of 5:00 pm
(Central time) on September 1, 2013 (the “Expiration Date”) with respect to any then unexercised portion thereof, unless terminated earlier as set forth below: 
 (a) Termination by Death. If the Optionee’s Service (as defined below) with the Company terminates by reason of death, or if the
Optionee dies within three (3) months after termination of such Service for any reason other than Cause (as defined below), this Option may

  

 2 

 
thereafter be exercised, to the extent the Option was exercisable at the time of such termination, by the legal representative of the estate or by the legatee of the Optionee under the will of
the Optionee, for a period of one (1) year from the date of death or until the Expiration Date of the Option, whichever period is the shorter. 
 (b) Termination by Reason of Disability. If the Optionee’s Service with the Company terminates by reason of Disability (as defined below), this Option may thereafter be exercised, to the
extent the Option was exercisable at the time of such termination, by the Optionee or personal representative or guardian of the Optionee, as applicable, for a period of one (1) year from the date of such termination of Service or until the
Expiration Date of the Option, whichever period is the shorter. 
 (c) Termination for Cause or Voluntary Termination. If
the Optionee voluntarily terminates his Service with the Company or if the Optionee’s Service is terminated for Cause, this Option shall terminate immediately and become void and of no effect. 
 (d) Other Termination. If the Optionee’s Service with the Company is involuntarily terminated for any reason other than for
Cause, death or Disability, this Option may be exercised, to the extent the Option was exercisable at the time of such termination, by the Optionee for a period of three (3) months from the date of such termination of Service or the Expiration
Date of the Option, whichever period is the shorter. 
 (e) Definition of Service. For purposes of this Agreement, the
term “Service” shall mean the Optionee’s employment with the Company. 
 (f) Definition of
Disability. For purposes of this Agreement, the term “Disability” shall have the meaning given to such term in Section 409A of the Internal Revenue Code of 1986, as amended, or any successor provision thereto. 

(g) Definition of Cause. For purposes of this Agreement, the term “Cause” shall mean (i) the Optionee’s
commission of an act of fraud, embezzlement, theft or other criminal act constituting a felony, (ii) the Optionee’s willful or wanton disregard of the rules or policies of the Company which results in a material loss, damage or injury to
the Company, (iii) the repeated failure of the Optionee to perform duties consistent with his position or to follow or comply with the reasonable directives of the Company’s Board of Directors or the Optionee’s superior(s) after
having been given notice thereof, (iv) the Optionee’s material breach of any provision contained in any written non-competition, confidentiality or non-disclosure agreement between the Company and the Optionee, or (v) if applicable,
any other event that allows the Company to terminate the Optionee’s Service for “cause” pursuant to a written employment agreement. 
 6. No Right to Continued Service. The grant of the Option shall not be construed as giving Optionee the right to be retained in the employ of the Company. 
 7. Amendment to Option. The Company may waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue,
cancel or terminate, the Option, prospectively or retroactively; provided that any such waiver, amendment, alteration, suspension, discontinuance, cancellation or termination that would adversely affect the rights of the Optionee or any holder or
beneficiary of the Option shall not to that extent be effective without the consent of the Optionee, holder or beneficiary affected. 
  

 3 

 8. Limited Transferability. During the Optionee’s lifetime the Option can be
exercised only by the Optionee, except as otherwise provided in Section 5(a) or (b) above or in this Section 8. The Option may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the
Optionee other than (a) to a Permitted Transferee (as defined below) on the terms set forth below or (b) by will or the laws of descent and distribution. Any attempt to otherwise transfer the Option shall be void. No transfer of this
Option by the Optionee by will or by laws of descent and distribution shall be effective to bind the Company unless the Company shall have been furnished with written notice thereof and an authenticated copy of the will and/or such other evidence as
the Committee may deem necessary or appropriate to establish the validity of the transfer. The Optionee may transfer the Option to a Permitted Transferee provided that (i) this Option shall have fully vested, (ii) there is no consideration
for such transfer (other than receipt by the Optionee of an interest in an entity that is a Permitted Transferee), (iii) the Optionee (or the Optionee’s estate or representative) shall remain obligated to satisfy all income or other tax
withholding obligations associated with the exercise of this Option, (iv) the Optionee shall notify the Company in writing prior to such transfer and disclose to the Company the name and address of the Permitted Transferee and the relationship
of the Permitted Transferee to the Optionee, and (v) such transfer shall be effected pursuant to transfer documents in a form approved by the Company. A Permitted Transferee may not further assign or transfer any the Option otherwise than by
will or the laws of descent and distribution. For purposes of this Agreement, the term “Permitted Transferee” means, with respect to the Optionee, (x) any child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law of the Optionee, including adoptive relationships, and (y) a trust in which the Optionee or the persons described in the preceding clause
(x) have more than fifty percent (50%) of the beneficial interest. 
 9. Reservation of Shares. At all times
during the term of the Option, the Company shall use its best efforts to reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of this Agreement. 
 10. Restrictions on Purchase and Sale Shares. The Company shall be obligated to sell or issue Shares pursuant to the exercise of this
Option only in the event that the Shares are at that time effectively registered or otherwise exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”). In the event that the Shares are not registered
under the 1933 Act, the Optionee hereby agrees that, as a further condition to the exercise of this Option, the Optionee, if the Company so requests, will execute an agreement in form satisfactory to the Company in which the Optionee represents that
he or she is purchasing the shares for investment purposes, and not with a view to resale or distribution. The Optionee further agrees that if the Shares to he issued upon the exercise of this Option are not subject to an effective registration
statement filed with the Securities and Exchange Commission pursuant to the requirements of the 1933 Act, such Shares shall bear an appropriate restrictive legend 
 11. Severability. If any provision of this Agreement is, or becomes, or is deemed to be, invalid, illegal, or unenforceable in any jurisdiction or to either party, such provision shall be construed
or deemed amended to conform to the applicable Laws, or if it cannot be construed or deemed amended without, in the determination of the Company’s Board of Directors or a duly authorized committee thereof, materially altering the intent of this
Agreement, such provision shall he stricken as to such jurisdiction or party, and the remainder of this Agreement shall remain in lull force and effect. 
  

 4 

 12. Notices. All notices required to he given under this Agreement shall be deemed to
have been given (a) in the case of personal delivery, on the date of such delivery, or (b) in the case of mailing, on the third business day following the date of such mailing, in either case addressed to the party to be notified at the
address set forth below or to such other address as such party may provide in writing from time to time. 
  

			
	To the Company:	  	 SurgiVision, Inc.
 One
Commerce Square
 Suite 2550
 Memphis,
TN 38103
 Attention: Secretary

		
	To the Optionee:	  	The address then maintained with respect to the Optionee in the Company’s records.

 13. Governing Law. The validity, construction and effect of this Agreement shall be determined in accordance with the laws of the
State of Delaware without giving effect to conflicts of laws principles. 
 14. Successors in Interest. This Agreement
shall inure to the benefit of and be binding upon any successor to the Company. This Agreement shall inure to the benefit of the Optionee’s administrators, executors, heirs, legal representatives, Permitted Transferees and successors. All
obligations imposed upon the Optionee and all rights granted to the Company under this Agreement shall be binding upon the Optionees administrators, executors, heirs, legal representatives, Permitted Transferees and successors. 
 [The next page is the signature page] 
  

 5 

 IN WITNESS WHEREOF, the parties have executed this Non-Qualified Stock Option
Agreement to be effective as of the day and year first above written. 
  

			
	SURGIVISION, INC.
		
	By:	 	 

	Name:	 	 OSCAR THOMAS

	Title:	 	 VP, BUSINESS AFFAIRS

	
	
 

	Kimble L. JenkinsSponsored Research Agreement

 Exhibit 10.26 
 SPONSORED RESEARCH AGREEMENT 
 This Agreement is entered into
by Surgi-Vision Inc., incorporated in the State of Delaware (“SVI”), and the Regents of the University of California on behalf of its San Francisco campus (“UCSF”), with an administrative office located at 185 Berry Street, Suite
4603, San Francisco, California, 94143-1016, the above named entities hereinafter identified together as “the Parties” and in the singular as “the Party”. 
 RECITALS 
 WHEREAS, SVI has developed proprietary technology
related to Interventional Magnetic Resonance (“IMR”) including technology related to MRI-safe devices, MR Guided therapeutic procedures and the MR Guided placement of Deep Brain Stimulation (“DBS”) leads in the body; 

WHEREAS, UCSF employees, Philip Starr, M.D., Paul Larson, M.D., and Alastair Martin, Ph.D. (the “Researchers”) have performed
research in IMR in placing DBS leads in an open magnet, such as described, for example, in Placement of Deep Brain Stimulator Electrodes Using Real-Time High-Field Interventional Magnetic Resonance Imaging, Martin et al., Mag. Res. in
Medicine, 54:1107-1114 (2005); and 
 WHEREAS, the Parties desire to collaborate to advance the technology to facilitate the
clinical use of IMR to place DBS leads. 
 In view of the foregoing, the Parties agree to the following terms of this Agreement.

 AGREEMENT 
 1. Confidentiality 
 1.1 In connection with work performed pursuant to this Agreement, the Parties may
find it necessary or desirable to disclose to the each other certain proprietary and confidential information relating to product concepts, operation, ideas, and developments (defined below as the “Confidential Information”). 

 1.2 “Confidential Information” means information disclosed by one Party to another
that has value to the formation and operation of the disclosing Party’s business, which is marked “Confidential”, or if orally disclosed, reduced to writing within thirty (30) days of disclosure. Notwithstanding the foregoing,
“Confidential Information” shall not include information which: (a) is in the public domain when received from a Party; or (b) was known to a Party prior to its receipt from the other party, as shown by written records in
existence prior to such disclosure; or (c) is independently developed by one Party as evidenced by its written records; or (d) is required to be disclosed by law. No Party shall be liable under this Agreement for disclosure or use of
Confidential Information which: (i) is published or otherwise enters the public domain through no fault of the receiving party; or (ii) was lawfully obtained by the receiving party from a third party entitled to disclose it. 
 1.3 Restrictions on Use and Disclosure. Without the written permission of the disclosing Party, the receiving party will not disclose
Confidential Information to any third party or use Confidential Information for any purpose other than the purpose for which it was disclosed. The Parties will protect Confidential Information from unauthorized disclosure or use through such
precautions as the receiving Party employs for its own information of a similar nature, and will, in any event, employ reasonable precautions. Upon request, the receiving Party will promptly return all Confidential Information furnished by the
disclosing party in written or other tangible form and all copies and other reproductions of Confidential Information made by the receiving Party. To assist the receiving Party in identifying Confidential Information, the disclosing Party will mark
electronic or hard copy materials “Confidential.” Oral confidential disclosures shall be reduced to writing and marked confidential within thirty (30) days of disclosure. 
  

 2 

 1.4 UCSF is free to publish or otherwise disclose activities performed or data arising from
activities performed under this Agreement. However, UCSF and Researchers must first provide a review copy of a planned disclosure to a third party to SVI at least thirty (30) days prior thereto to allow sufficient time to review the
document/planned disclosure to confirm no SVI Confidential Information is included, that SVI technology is correctly described and/or allow SVI, at its discretion, to request that patent applications be pursued for inventions that may be described
in the document/planned disclosure. In no event shall the delay to publish exceed a total of sixty (60) days. 
 2.
Research Activities 
 2.1 UCSF agrees that the Researchers shall reasonably carry out research activities substantially as
described in the Project Plan attached at Appendix A and to cooperate with SVI to facilitate a timely and successful completion of the Project Plan. The Project Plan describes the activities to be carried out under this Agreement, including:
(a) Continued Clinical Assessment of Efficacy and Safety of IMR Guidance; and (b) Advanced Technology Assessment, including an integrated head-holder and a new aiming device. 
 2.2 UCSF and/or its Researchers will give SVI periodic reports on the status of the Project Plan and promptly notify SVI on the date of the
first clinical IMR DBS placement procedure on a human patient conducted after the Effective Date of this Agreement. The notification will be used to determine the term of the Agreement as provided below in section 6.1. 
 2.3 UCSF and the Researchers agree to comply with all appropriate regulations in carrying out research activities under this Agreement,
including all medical and human study protocols, and FDA and other appropriate rules and regulations. 
 3. SVI Support 

 3.1 SVI agrees to provide to UCSF funding in the amount of $[***] to be allocated and applied by UCSF and the Researchers to
carry out the goals and activities described in the Project Plan. 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 3 

 [***]. The monies will be made payable to “The Regents of the University of
California” and transmitted to the address below unless such address is updated in writing by UCSF. 
 University of
California San Francisco 
 UCSF Accounting - EMF 
 1855 Folsom Street, Suite 425 
 San Francisco, CA 94143-0897 
 3.2 SVI agrees to provide technical assistance and cooperate with Researchers to facilitate the goals and actions described in the Project
Plan. 
 4. Independent Contractor 
 4.1 SVI and UCSF and its’ Researchers are independent contractors for all purposes of this Agreement. Neither UCSF or Researchers or any agent, representative, contractor or employee of UCSF will be
considered an agent, representative or employee of SVI for any purpose. Conduct, direction and control of the work performed under this Agreement by UCSF and Researchers lies solely with same. 
 5. Intellectual Property 
 5.1 “Intellectual Property” means any inventions made in the direct performance of the Project Plan. 
 5.2 The Parties will each have the right to use data generated from the direct performance of the Project Plan. 
 5.3 For SVI wholly-owned Intellectual Property, SVI shall grant to UCSF and the Researchers a royalty-free, non-exclusive license to practice the technology for non commercial research purposes only.

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 4 

 5.4 For UCSF wholly-owned Intellectual Property, UCSF shall grant to SVI a royalty-free,
non-exclusive license to practice the technology for research purposes only. 
 5.5 For USCF wholly or partially/jointly owned
Intellectual Property, UCSF agrees to offer SVI the first opportunity to enter into a royalty-bearing commercial (exclusive or non-exclusive) license, as appropriate, at a commercially-reasonable royalty rate. SVI may exercise such opportunity by
notifying UCSF of its intent to do so, within ninety (90) days of written notice by UCSF of such Intellectual Property, such notice will be no earlier than after a patent application for the invention(s) has been filed. Any exclusive license
shall allow the Researchers and UCSF the ability to practice the technology covered by the license or assignment for research purposes. Should UCSF and SVI be unable to agree to terms for such commercial license or assignment within one hundred and
eight days (180) days from SVI’s exercise of the opportunity, UCSF shall be free to negotiate with a third party. However, should UCSF reach a provisional agreement with any such third party within ninety days (90) of UCSF and SVI
failing to come to agreement on terms for a commercial license, as described herein, SVI will have a thirty (30) day period from the receipt of notice of the third party provisional agreement, to exercise a right of first refusal on financial
terms and conditions as set forth in such proffered third party agreement. 
 5.6 In the event of a joint invention resulting in
co-owned Intellectual Property arising from this Agreement, SVI and UCSF will cooperate and mutually agree upon outside patent counsel and the preparation, filing, prosecution and maintenance of any patent applications and resulting patents covering
same, including the right for both Parties to review and approve any such patent application filing. 
 6. Term and
Termination 
 6.1 This Agreement is effective on the last signature date of the undersigned Parties (“the Effective
Date”) and continues in effect for one year from the date of a first clinical IMR DBS placement procedure on a human patient conducted after the Effective Date of this Agreement if the payments to UCSF under section 3.1 above has been made.

  

 5 

 6.2 The Agreement may be extended for an additional one (1) year period by mutual
written agreement of the Parties. 
 6.3 Survival of Agreement Provisions. The Intellectual Property, Joint Research (for
inventions arising from activities prior to the termination date), and Confidentiality provisions herein will continue to apply after expiration of the Agreement and will survive the expiration or other termination of this Agreement. 
 7. Joint Research 
 7.1 SVI, UCSF and Researchers contemplate that performance of activities arising from this Agreement may include joint or collaborative research and activities between the Parties and/or affiliates or successors in interest thereof. Hence,
this Agreement may be asserted as a joint research agreement for the performance of experimental, developmental or research work in the field of Interventional Magnetic Resonance (IMR) deemed to have been owned by the same person or subject to an
obligation of assignment to the same person under 35 USC § 103(c) as provided for in the Cooperative Research and Technology Enhancement Act of 2004. 
 8. Covenants and Warranties 
 8.1 UCSF certifies to the best of its current
knowledge that there is no prior, preexisting or existing agreement with a third party that conflicts with this Agreement. 
 8.2 UCSF certify that it/they has/have the full right and authority to enter into this Agreement. 
 8.3 UCSF certifies
that all of their employees (including other principal investigators, students and/or faculty), whose services may be used to carry out research and/or development activities under this Agreement, are or will be appropriately informed of the terms
of this Agreement, and that all such persons are under legal obligation to UCSF by contract or otherwise, sufficient to fully comply with this Agreement, including for persons that may be inventors, legal obligations to assign rights to any
inventions and associated operational copyrights to UCSF. 
  

 6 

 9. Miscellaneous 
 9.1 This agreement will be governed by and construed in accordance with the laws of the State of California. Every provision of this agreement is intended to be severable. If any term or provision hereof
is illegal or invalid for any reason whatsoever, such illegality or invalidity shall not affect the remainder of this agreement. 
 9.2 Notice. 
  

			
	To UCSF	  	To Surgi-Vision, Inc.:
		
	Attn: Director	  	Kimble Jenkins
		
	University of California at San Francisco	  	President & CEO
		
	185 Berry Street, Suite 4603	  	50 North Front St.; 19th Floor
		
	San Francisco, CA 94143-1016	  	Memphis, TN 38103

  

 7 

 IN WITNESS WHEREOF, the undersigned parties have agreed to the foregoing and the undersigned
Researchers have read and understand this agreement. 
  

					
	On behalf of USCF	 		 	On behalf of Surgi-Vision, Inc.
			
	/s/ Jim Kiriakis	 		 	/s/ Kimble Jenkins
	Jim Kiriakis	 		 	Kimble Jenkins, President and CEO
	 Industry Contracts Manager
 Office of Sponsored Research
 University of California
 San Francisco
	 		 	
			
	Date: 8/15/07	 		 	Date: 8/24/07

  

					
	Read and Understood:	 		 	
			
	/s/ Phillip Starr	 		 	8/13/07
	Phillip Starr, M.D.	 		 	(Date)
			
	/s/ Paul Larson	 		 	8/10/07
	Paul Larson, M.D.	 		 	(Date)
			
	/s/ Alastair Martin	 		 	8/10/07
	Alastair Martin, Ph.D.	 		 	(Date)

  

 8 

 Appendix A 
 Project Plan 
  

 9 

 Surgi-Vision Scope of Work & Budget Justification 
 “MRI Implanation for Deep Brain Stimulation (DBS)” 
 UCSF Investigators 
 Drs. Philip Starr, Paul Larson, Alastair
Martin & Jill Ostrem 
 March 1, 2007-February 29, 2008 
 SCOPE OF WORK 
 [***]

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 10 

 FIRST AMENDMENT TO 
 SPONSORED RESEARCH AGREEMENT 
 This First Amendment to
Sponsored Research Agreement (the “Amendment”) is made effective as of December 1, 2008 (the “Amendment Effective Date”), by and between SurgiVision, Inc. (f/k/a Surgi-Vision, Inc.), a Delaware corporation
(“SVI”), and the Regents of the University of California on behalf of its San Francisco campus (“UCSF”). 
 WHEREAS, SVI and UCSF entered into that certain Sponsored Research Agreement in August 2007 (the “Research Agreement”); and 
 WHEREAS, SVI and UCSF desire to amend and modify the Research Agreement in the manner set forth below; 
 NOW, THEREFORE, for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties agree as
follows: 
 1. Defined Terms. Capitalized terms used but not defined in this Amendment shall have the meanings ascribed
to such terms in the Research Agreement. 
 2. Term of Research Agreement. Subject to Section 4 below, the
term of the Research Agreement shall continue through April 30, 2009 (the “Expiration Date”). 
 3.
Additional SVI Support. In addition to the funding described in Section 3.1 of the Research Agreement (which was paid by SVI to UCSF in accordance with the Research Agreement), SVI agrees, subject to Section 4 below, to
provide to UCSF funding in an amount up to $[***]. Such funding shall be allocated and applied by UCSF (a) to carry out research activities under the Research Agreement during the 5-month period commencing with the Amendment Effective Date and
continuing through the Expiration Date, and (b) substantially in accordance with the itemized budget attached hereto as Appendix A. SVI shall remit monthly payments to UCSF based on monthly invoices submitted to SVI by UCSF. Such
invoices shall itemize the direct costs and identify the facility and administrative costs. Invoices submitted to SVI shall be paid by SVI within 30 days of receipt. 
 4. UC Discovery Grant. UCSF acknowledges that (a) SVI is the industry sponsor for a research proposal entitled “Optimized Methodology for Implantation of DBS Electrodes” (Principal
Investigator: Alastair J. Martin, Ph.D.) submitted pursuant to the UC Discovery Grant Request for Proposals, and (b) if that proposed project is approved for UC Discovery Grant funding by the Industry-University Cooperative Research Program,
SVI intends to negotiate with UCSF with the goal of executing a mutually acceptable research agreement (the “UC Discovery Agreement”). If SVI and UCSF enter into the UC Discovery Agreement, then the term of the Research Agreement
shall expire as of the effective date of the UC Discovery Agreement and SVI shall not be obligated to provide funding under the Research Agreement for any period of time beyond that date. Notwithstanding the expiration of the Research Agreement, the
Intellectual Property, Joint Research and Confidentiality provisions of the Research Agreement shall continue to apply as otherwise provided in Section 6.3 of the Research Agreement. 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 1 

 5. Notice to SVI. SVI’s address for notice under the Research Agreement is:

 SurgiVision, Inc. 
 Attention: CEO 
 One Commerce Square 
 Suite 2550 
 Memphis, TN 38103 
 with a copy to: 
 SurgiVision, Inc. 
 Attention: VP, Business Affairs 
 One Commerce Square 
 Suite 2550 
 Memphis, TN 38103 
 [The next page is the signature page] 
  

 2 

 IN WITNESS WHEREOF, the Parties have agreed to the foregoing and the undersigned Researchers
have read and understand this Amendment. 
  

					
	On behalf of UCSF	 		 	On behalf of SVI
			
	/s/ Kent Iwamiya	 		 	/s/ Oscar Thomas
	Kent Iwamiya	 		 	OSCAR THOMAS
	Industry Contracts Officer	 		 	VICE PRESIDENT, BUSINESS AFFAIRS
	 Office of Sponsored Research
 University of California
 San Fransisco
	 		 	
			
	Date: 2/25/09	 		 	Date: February 16, 2009

  

					
	Read and Understood:	 		 	
			
	/s/ Phillip Starr	 		 	2/17/09
	Phillip Starr, M.D.	 		 	Date
			
	/s/ Paul Larson	 		 	2/18/09
	Paul Larson, M.D.	 		 	Date
			
	/s/ Alastair Martin	 		 	2/24/09
	Alastair Martin, Ph.D.	 		 	Date

  

 3 

 Appendix A 
 Budget 
 [See Attached] 
  

 4 

 [***] 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 5 

 SECOND AMENDMENT TO 
 SPONSORED RESEARCH AGREEMENT 
 This Second Amendment
to the Sponsored Research Agreement (“Second Amendment”) is made effective as of May 1, 2009 (the “Second Amendment Effective Date”) by and between SurgiVision, Inc. (f/k/a Surgi-Vision, Inc.), a Delaware corporation
(“SVI”), and The Regents of the University of California on behalf of its San Francisco campus (“UCSF”). 
 RECITALS 
 A. SVI and UCSF entered into a Sponsored Research Agreement in August 2007, which was subsequently
amended effective as of December 1, 2008 (as amended, the “Research Agreement”). 
 B. SVI and UCSF wish to
further amend the terms of the Research Agreement as set forth below. 
 NOW, THEREFORE, for good and valuable
consideration, the sufficiency and receipt of which are hereby acknowledged, it is hereby agreed as follows: 
 1. Capitalized
terms used but not defined in this Second Amendment shall have the meanings ascribed to such terms in the Research Agreement. 
 2. Subject to Section 5 below, the term of the Research Agreement shall continue through April 30, 2010 (the “Expiration Date”). 
 3. Subject to Section 5 below, for the one-year period commencing with the Second Amendment Effective Date and continuing through the Expiration Date, SVI shall provide to UCSF funding in an amount
up to $[***] (the “Additional Funding”). The Additional Funding shall be allocated and applied by UCSF (a) to carry out research activities substantially as described in the Scope of Work attached hereto as Exhibit A (the
“SOW”), and (b) substantially in accordance with the itemized budget attached hereto as Exhibit B. Subject to Section 5 below,

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 1 

 
SVI shall pay to UCSF the Additional Funding in [***] each according to the following schedule: [***]. For purposes of the Research Agreement (as amended by this Second Amendment), the term
“Project Plan” shall hereinafter include, without limitation, the SOW attached hereto as Exhibit A. 
 4. Installment
payments of the Additional Funding shall be made payable to “The Regents of the University of California” and transmitted to the address below unless such address is updated by written notice to SVI from UCSF: 
 University of California San Francisco 
 UCSF Accounting – EMF 
 1855 Folsom Street, Suite 425 
 San Francisco, CA 94143-0897 
 5. UCSF acknowledges that (a) SVI is the industry sponsor for a research proposal entitled “Optimized Methodology for Implantation of DBS Electrodes” (Principal Investigator: Alastair J.
Martin, Ph.D.) submitted pursuant to the UC Discovery Grant Request for Proposals, and (b) if that proposed project is approved for UC Discovery Grant funding by the Industry-University Cooperative Research Program, SVI intends to negotiate
with UCSF with the goal of executing a mutually acceptable research agreement (the “UC Discovery Agreement”). If SVI and UCSF enter into the UC Discovery Agreement, then (x) the term of the Research Agreement shall expire as of the
effective date of the UC Discovery Agreement, (y) SVI shall not be obligated to pay any further installments of the Additional Funding, and (z) UCSF shall promptly return to SVI that portion of any installment of the Additional Funding
paid by SVI that is attributable to the period of time that follows the expiration of the Research Agreement. Notwithstanding the expiration of the Research Agreement, the Intellectual Property, Joint Research and Confidentiality provisions of the
Research Agreement shall continue to apply as otherwise provided in Section 6.3 of the Research Agreement. 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 2 

 5. Section 5 of the Research Agreement (Intellectual Property) is hereby amended by
adding the following section 5.7: 
 “5.7 Notwithstanding the provisions of section 5.5 above to the contrary, with respect
to any UCSF wholly or partially/jointly owned Intellectual Property that is dominated by patent rights (whether pursuant to an issued patent or pending patent application) currently owned or controlled by SVI (“Dominated IP”), UCSF hereby
grants to SVI an irrevocable fully paid-up, non-royalty bearing, worldwide non-exclusive license, with the right to sublicense, under the Dominated IP to make, have made, use, import, offer for sale and sell products and processes covered by the
Dominated IP. UCSF shall, upon SVI’s written request, file patent application(s) for any such Dominated IP, provided that SVI shall reimburse UCSF for the prosecution costs and expenses incurred by UCSF with respect to any such application(s)
requested by SVI.” 
 6. UCSF shall provide SVI with information reasonably requested by SVI relating to any clinical
procedures performed using SVI’s DBS implantation platform as contemplated in the SOW, except information that is subject to patient confidentiality laws or that UCSF is otherwise prohibited from providing to SVI pursuant to applicable law.

 7. The Exhibits attached to this Second Amendment are hereby incorporated into and made a part of this Second Amendment.

 8. Except as expressly provided in this Second Amendment, all other terms, conditions and provisions of the Research
Agreement shall continue in full force and effect as provided therein. 
 [The next page is the signature page] 
  

 3 

 IN WITNESS WHEREOF, SVI and UCSF have entered into this Second Amendment to be
effective as of the date first set forth above. 
  

									
	 THE REGENTS OF THE
 UNIVERSITY OF CALIFORNIA
	 		 	SURGIVISION, INC.
					
	By	 	/s/ Kent Iwamiya	 		 	By	 	/s/ Kim Jenkins
	Name:	 	Kent Iwamiya	 		 	Name:	 	KIM JENKINS
	Title:	 	 Industry Contracts Officer
 Office of Sponsored Research
 University of California
 San Francisco
	 		 	Title:	 	CEO
					
	Date:	 	7-10-09	 		 	Date:	 	7/15/2009

 Each of the undersigned Researchers, while not
a party to this Second Amendment, hereby acknowledges that he has read the Second Amendment and understands his obligations as an UCSF employee hereunder: 
  

									
				
	/s/ Alastair Martin	 		 		 	
	Name:	 	Alastair Martin, PhD	 		 		 	
	Date:	 	July 7, 2009	 		 		 	
				
	/s/ Phillip Starr	 		 		 	
	Name:	 	Phillip Starr	 		 		 	
	Date:	 	July 9, 2009	 		 		 	
					
	By	 	 	 		 		 	
					
	Name:	 	 	 		 		 	
					
	Date:	 	 	 		 		 	

  

 4 

 Exhibit A 
 Scope of Work 
 [See Attached] 
  

 5 

 Surgi-Vision Scope of Work & Budget 
 Justification 
 “MRI Implanation for Deep Brain Stimulation (DBS)” 
 UCSF Investigators 
 Drs. Philip Starr, Paul Larson, Alastair Martin & Jill Ostrem 
 May 1, 2009 - April 30, 2010 
 SCOPE OF WORK 
 [***] 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 6 

 Exhibit B 
 Research Budget 
 [See Attached] 
  

 7 

 [***] 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 8 

 THIRD AMENDMENT TO 
 SPONSORED RESEARCH AGREEMENT 
 This Third Amendment to
Sponsored Research Agreement (this “Third Amendment”) is made effective as of November 2, 2009 (the “Third Amendment Effective Date”) by and between SurgiVision, Inc., a Delaware corporation
(“SVI”), and The Regents of the University of California on behalf of its San Francisco campus (“UCSF”). 
 RECITALS 
 A SVI and UCSF entered into a Sponsored Research Agreement in
August 2007, as amended pursuant that certain First Amendment to Sponsored Research Agreement made effective as of December 1, 2008 and that certain Second Amendment to Sponsored Research Agreement made effective as of May 1, 2009 (as
amended, the “Research Agreement”). 
 B. UCSF submitted a research proposal entitled “Optimized
Methodology for Implantation of DBS Electrodes” (Principal Investigator: Alastair J. Martin, Ph.D.) pursuant to the UC Discovery Grant Request for Proposals (the “Research Project”). 
 C. The Research Project has been approved for UC Discovery Grant funding by the Industry-University Cooperative Research Program.

 D. The Second Amendment to Sponsored Research Agreement made effective as of May 1, 2009 (the “Second
Amendment”) contemplated that upon approval of the Research Project for UC Discovery Grant funding, SVI and UCSF would negotiate a new UC Discovery Agreement, which agreement would replace the Research Agreement. 
 E. Notwithstanding the provisions of the Second Amendment to the contrary, in lieu of entering into the UC Discovery Agreement, SVI and UCSF
wish to further amend the terms of the Research Agreement as set forth below to address the Research Project and SVI’s support with respect thereto. 
 NOW, THEREFORE, for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, it is hereby agreed as follows: 
 1. Defined Terms. Capitalized terms used but not defined in this Third Amendment shall have the meanings ascribed to such terms in
the Research Agreement. 
 2. Term of Research Agreement. 
 (a) Unless terminated earlier as provided below, the term of the Research Agreement shall continue through November 1,
2011 (the “Expiration Date”). 
  

 1 

 (b) If either SVI or UCSF (or any Principal Investigator) materially
defaults in the performance of any duty or obligation imposed upon it under the Research Agreement (as amended by this Third Amendment) and such default continues for sixty (60) days after written notice thereof has been given to the defaulting
party by the other party, such other party may (but need not) give notice of the immediate termination of the Research Agreement. 
 3. SVI Support for Research Project. 
 (a) SVI’s funding obligations under Section 3
of the Second Amendment are hereby terminated. 
 (b) With respect to the two-year period commencing with the
Third Amendment Effective Date and continuing through the Expiration Date, SVI shall provide to UCSF funding in an aggregate amount up to $[***] (the “Cash Funding”). UCSF shall allocate and apply the Cash Funding (i) to carry
out research activities for the Research Project substantially as described in the Scope of Work attached hereto as Exhibit A (the “Research Project SOW”), and (ii) substantially in accordance with the itemized budget
for the Research Project attached hereto as Exhibit B. SVI shall pay to UCSF the Cash Funding in [***] according to the following schedule: [***]. For purposes of the Research Agreement (as amended by this Third Amendment), the term
“Project Plan” shall hereinafter include, without limitation, the Research Project SOW attached hereto as Exhibit A. 
 (c) In addition to the Cash Funding, and as further support for the Research Project, SVI shall make the in-kind contributions to UCSF set forth on Exhibit C attached hereto (the “In-Kind
Contributions”). UCSF and SVI acknowledge and agree that the value of the In-Kind Contributions, as reflected on Exhibit C, will be amortized over the two-year period commencing with the Third Amendment Effective Date and continuing
through the Expiration Date, resulting in an annual valuation of the In-Kind Contributions equal to $[***]. UCSF shall use the In-Kind Contributions (i) to carry out research activities for the Research Project substantially as described in the
Research Project SOW, and (ii) with appropriate care in accordance with all instructions for use and in compliance with applicable law. 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 2 

 (d) Installment payments of the Cash Funding shall be made payable to
“The Regents of the University of California” and transmitted to the address below unless such address is updated by written notice to SVI from UCSF: 
 University of California San Francisco 
 UCSF Accounting – EMF 
 1855 Folsom Street, Suite 425 
 San Francisco, CA 94143-0897 
 (e) In the event the Research
Agreement is terminated by SVI pursuant to Section 2(b) above prior to the Expiration Date, UCSF shall promptly return to SVI that portion of any installment of the Cash Funding paid by SVI that is attributable to the period of time that
follows the termination of the Research Agreement. 
 4. Human Subject Research. UCSF and the Principal Investigators
understand that the research covered by the Research Agreement involving human subjects (“Human Subject Research”) requires appropriate documentation, review and approval by UCSF’s Institutional Review Board (the
“IRB”) and compliance with all IRB recommendations and requirements. UCSF and the Principal Investigators acknowledge and agree that (a) a copy of each IRB approval relating to Human Subject Research covered by the Research
Agreement will be provided to SVI, (b) all clinical studies will be conducted under the supervision of qualified and licensed physicians, (c) all FDA regulations for Human Subject Research will be strictly observed, and (d) no Human
Subject Research will be commenced before IRB approval has been granted. UCSF and the Principal Investigators assume full responsibility for any clinical decisions made as a result of data, directly or indirectly, generated during any research
covered by the Research Agreement. 
 5. Clinical Data. 
 (a) UCSF shall provide SVI with information reasonably requested by SVI relating to any clinical
procedures performed using SVI’s ClearPointTM Neuro
Intervention System as contemplated in the Research Project SOW, except information that is subject to patient confidentiality laws or that UCSF is otherwise prohibited from providing to SVI pursuant to applicable law. 
  

 3 

 (b) UCSF agrees to purge all patient identifiers from all information it
provides to SVI hereunder. Nevertheless, and to the extent required by the provisions of the Health Insurance Portability and Accountability Act (“HIPAA”) and the regulations promulgated thereunder, SVI does hereby assure UCSF that
it will appropriately safeguard protected health information (“PHI”) made available to or obtained by SVI hereunder. Without limiting the obligations of SVI otherwise set forth herein or imposed by applicable law, SVI agrees to
comply with applicable requirements of law relating to PHI. Specifically, SVI shall: 
 (i) not use or disclose
PHI other than as permitted or required by the Research Agreement (including this Third Amendment) or as permitted or required by law; 
 (ii) implement administrative, physical and technical safeguards that reasonably and appropriately protect the confidentiality, integrity and availability of the electronic PHI that it creates, receives,
maintains or transmits on behalf of UCSF and use appropriate safeguards to prevent use or disclosure of PHI other than as provided for herein; 
 (iii) report to UCSF any use or disclosure of PHI not provided for herein, and any security incident relating to PHI, of which SVI becomes aware; 
 (iv) ensure that any subcontractors or agents to whom SVI provides PHI received from, or created or received by SVI on behalf
of, UCSF agree to essentially the same restrictions and conditions that apply to SVI with respect to PHI and implement reasonable and appropriate safeguards with respect to such information; 
 (v) make PHI available to UCSF in accordance with applicable law; 
 (vi) permit UCSF to access PHI to make or permit others to make amendments to PHI in accordance with applicable law;

 (vii) make available to UCSF the information in SVI’s possession required to provide an accounting of
SVI’s disclosures of PHI as required by applicable law; 
 (viii) make SVI’s internal practices, books,
and records relating to the use and disclosure of PHI received from UCSF available to the Secretary of the United States Department of Health & Human Services for purposes of determining UCSF’s compliance with applicable law;

 (ix) use reasonable commercial efforts to mitigate any harmful effect that is known to SVI of a use or
disclosure of PHI by SVI in violation of the requirements set forth herein; and 
 (x) upon expiration or
termination of the Research Agreement, return to UCSF or destroy all PHI in its possession as a result of this Amendment and retain no copies of such PHI, if it is feasible to do so. If return or destruction is not feasible, SVI agrees to extend all
protections contained here to SVI’s use and/or disclosure of any retained PHI, and to limit further uses and/or disclosures to the purposes that make the return or destruction of the PHI infeasible. 
  

 4 

 (c) SVI agrees that it will negotiate in good faith an amendment hereto if
required by, and to the extent required by, the provisions of HIPAA and regulations promulgated thereunder, in order to assure that this Amendment is consistent therewith. 
 6. Prohibition on Practice of Medicine . Notwithstanding anything to the contrary contained herein, the parties acknowledge that SVI
is not authorized or qualified to engage in any activity which may be construed or deemed to constitute the practice of medicine. Accordingly, UCSF shall retain the authority to direct all medical decisions regarding the care and treatment of its
patients and shall assume full responsibility for any clinical decisions made as a result of data, directly or indirectly, generated during the research activities conducted. SVI shall neither exercise control over nor interfere with the
physician-patient relationship. To the extent any act or service required of SVI under the Research Agreement should be construed or deemed by a governmental authority, agency or court to constitute the practice of medicine, the performance of said
act or service by SVI shall be deemed waived and forever unenforceable. 
 7. Anti-Kickback Statute. In compliance with
the federal Medicare/Medicaid Anti-Kickback Statute, each party represents that the Cash Funding and In-Kind Contributions to UCSF have not been determined with regard to any implicit or explicit agreement to provide favorable procurement decisions
with regard to SVI’s products, and have not been given in exchange for such decisions. Each party further represents that such compensation has not been determined with regard to the value or volume of any business generated between the parties
and that such compensation is consistent with fair market value in arm’s length transactions. The compensation provided hereunder is directly related to the costs of carrying out research, and includes no incentive payment to any individual for
identifying or recruiting human subjects. The Research Agreement (including this Third Amendment) is not intended to, and does not, induce the referral of patients or to induce purchase of any items or services reimbursed by any federal or state
health care program. UCSF acknowledges that (a) it may be obligated to report the “no-charge” status of the In-Kind Contributions to Medicare, Medicaid and/or other federal health care programs, and (b) it may also have reporting
obligations to third parties (including, without limitation, Medicare) that require the allocation or classification of the In-Kind Contributions in accordance with particular reporting principles. UCSF agrees that it is solely responsible for any
such reporting, allocation(s) and/or classification(s). 
 8. FDA Regulations. UCSF understands and acknowledges that, as
of the Third Amendment Effective Date, pending 510(k) marketing clearance from the U.S. Food and Drug Administration (“FDA”), the In-Kind Contributions are not available for sale in the United States. Accordingly, notwithstanding
any provision herein to the contrary, pending 510(k) marketing clearance from the FDA, UCSF and the Principal Investigators shall use the In-Kind Contributions only to the extent such use is permitted under FDA regulations. Furthermore, pending
510(k) marketing clearance from the FDA, UCSF agrees that it will negotiate in good faith an amendment hereto if required by, and to the extent required by, FDA regulations in order to assure that this Amendment is consistent therewith. 

 

 5 

 9. Exhibits. The Exhibits attached to this Third Amendment are hereby incorporated
into and made a part of this Third Amendment. 
 10. Ratification of Research Agreement. Except as provided in this Third
Amendment, all other terms, conditions and provisions of the Research Agreement shall continue in full force and effect as provided therein. 
 [The next page is the signature page] 
  

 6 

 IN WITNESS WHEREOF, SVI and UCSF have entered into this Third Amendment to be
effective as of the date first set forth above. 
  

									
	 THE REGENTS OF THE UNIVERSITY
 OF CALIFORNIA
	 		 	SURGIVISION, INC.
					
	By	 	/s/ Jim Kiriakis	 		 	By	 	/s/ Kim Jenkins
	Name:	 	Jim Kiriakis	 		 	Name:	 	Kim Jenkins
		 	Industry Contracts Manager Office of Sponsored Research University of California	 		 	Title:	 	CEO
	Title:	 	San Francisco	 		 		 	
					
	Date:	 	Oct. 30, 2009	 		 	Date:	 	Oct. 30, 2009

 Each of the undersigned
Researchers, while not a party to this Third Amendment, hereby acknowledges that he has read the Third Amendment and understands his obligations as an UCSF employee hereunder: 
  

									
	/s/ Alastair J. Martin	 		 		 	
	Name: Alastair J. Martin, PhD	 		 		 	
	Date: November 2, 2009	 		 		 	
				
	 	 		 		 	
					
	Name:	 	 	 		 		 	
					
	Date:	 	 	 		 		 	
					
	By	 	 	 		 		 	
					
	Name:	 	 	 		 		 	
					
	Date:	 	 	 		 		 	

  

 7 

 Exhibit A 
 Scope of Work 
 [See Attached] 
  

 8 

 [***] 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 9 

 Exhibit B 
 Research Budget 
 [See Attached] 
  

 10 

 [***] 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 11 

 Exhibit C 
 In-Kind Contributions 
 [***] 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 12 

 ADDENDUM TO SPONSORED RESEARCH AGREEMENT 
 This Addendum to Sponsored Research Agreement (this “Addendum”) is made effective as of
February 4th, 2010 by and between SurgiVision, Inc.,
a Delaware corporation (“SVI”) and The Regents of the University of California on behalf of its San Francisco campus (“UCSF”). 
 RECITALS 
 A. SVI and UCSF entered into a Sponsored Research Agreement in
August 2007, as amended pursuant that certain First Amendment to Sponsored Research Agreement made effective as of December I, 2008, and that certain Second Amendment to Sponsored Research Agreement made effective as of May I, 2009, and that certain
Third Amendment to Sponsored Research Agreement made effective as of November 2, 2009 (as amended, the “Research Agreement”). 
 B. SVI and UCSF wish to supplement the terms of the Research Agreement as set forth below to address certain additional research activities. 
 NOW, THEREFORE, for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, it is hereby
agreed as follows: 
 1. Construction and Interpretation. The provisions of this Addendum supplement, and in no way
replace or supersede, the provisions of the Research Agreement. Without limiting the generality of the foregoing, the research activities and funding set forth in this Addendum (including the Exhibits hereto) are in addition to, and do not in any
way modify or replace, the research activities, funding and other support set forth in the Third Amendment to Sponsored Research Agreement with respect to the research proposal entitled “Optimized Methodology for Implantation of DBS
Electrodes”, for which UCSF received UC Discovery Grant support. 
 2. Additional Research Activities. UCSF will
perform the research activities described in the Research Project Scope of Work attached hereto as Exhibit A (the “Additional SOW”). 
 3. SVI Support for Additional Research Activities. SVI will provide to UCSF additional funding in an aggregate amount up to $[***] (the “Additional Funding”). UCSF will allocate and apply
the Additional Funding to carry out the research activities as described in the Additional SOW. SVI will pay to UCSF the Additional Funding in a single installment within thirty (30) days of the effective date of this Addendum. For the
avoidance of any doubt, this Addendum does not affect SVI’s funding obligations set forth in the Third Amendment to Sponsored Research Agreement. 
 IN WITNESS WHEREOF, SVI and UCSF have entered into this Addendum to be effective as of the date first set forth above. 
  

									
	 THE REGENTS OF THE
 UNIVERSITY OF CALIFORNIA
	 		 	SURGIVISION, INC.
					
	By:	 	/s/ Jim Kiriakis	 		 	By:	 	/s/ Oscar Thomas
	Name:	 	Jim Kiriakis	 		 	Name:	 	Oscar Thomas
	Title:	 	 Industry Contracts Manager
 Office of Sponsored Research
 University of California
 San Francisco
	 		 	Title:	 	Vice President, Business Affairs
					
	Date:	 	2/4/10	 		 	Date:	 	February 4, 2010

  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 13 

 Exhibit A to Addendum to Sponsored Research Agreement 
 Research Project Statement of Work: 
 [***] 
  

	[***]	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment. 

 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]